Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR) von García-Martínez, Juan M, Moran, Jennifer, Clarke, Rosemary G, Gray, Alex, Cosulich, Sabina C, Chresta, Christine M, Alessi, Dario R

Volltext

MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion von Chalishazar, Milind D, Wait, Sarah J, Huang, Fang, Ireland, Abbie S, Mukhopadhyay, Anandaroop, Lee, Younjee, Schuman, Sophia S, Guthrie, Matthew R, Berrett, Kristofer C, Vahrenkamp, Jeffery M, Hu, Zeping, Kudla, Marek, Modzelewska, Katarzyna, Wang, Guoying, Ingolia, Nicholas T, Gertz, Jason, Lum, David H, Cosulich, Sabina C, Bomalaski, John S, DeBerardinis, Ralph J, Oliver, Trudy G

Volltext

Combined Inhibition of mTOR and CDK4/6 Is Required for Optimal Blockade of E2F Function and Long-term Growth Inhibition in Estrogen Receptor-positive Breast Cancer von Michaloglou, Chrysiis, Crafter, Claire, Siersbaek, Rasmus, Delpuech, Oona, Curwen, Jon O, Carnevalli, Larissa S, Staniszewska, Anna D, Polanska, Urszula M, Cheraghchi-Bashi, Azadeh, Lawson, Mandy, Chernukhin, Igor, McEwen, Robert, Carroll, Jason S, Cosulich, Sabina C

Volltext

Kinase-substrate enrichment analysis provides insights into the heterogeneity of signaling pathway activation in leukemia cells von Casado, Pedro, Rodriguez-Prados, Juan-Carlos, Cosulich, Sabina C, Guichard, Sylvie, Vanhaesebroeck, Bart, Joel, Simon, Cutillas, Pedro R

Volltext

AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules von Guichard, Sylvie M, Curwen, Jon, Bihani, Teeru, D'Cruz, Celina M, Yates, James W T, Grondine, Michael, Howard, Zoe, Davies, Barry R, Bigley, Graham, Klinowska, Teresa, Pike, Kurt G, Pass, Martin, Chresta, Christine M, Polanska, Urszula M, McEwen, Robert, Delpuech, Oona, Green, Stephen, Cosulich, Sabina C

Volltext

Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer von Pancholi, Sunil, Leal, Mariana Ferreira, Ribas, Ricardo, Simigdala, Nikiana, Schuster, Eugene, Chateau-Joubert, Sophie, Zabaglo, Lila, Hills, Margaret, Dodson, Andrew, Gao, Qiong, Johnston, Stephen R, Dowsett, Mitch, Cosulich, Sabina C, Maragoni, Elisabetta, Martin, Lesley-Ann

Volltext

AKT/mTORC2 Inhibition Activates FOXO1 Function in CLL Cells Reducing B-Cell Receptor-Mediated Survival von Cosimo, Emilio, Tarafdar, Anuradha, Moles, Michael W, Holroyd, Ailsa K, Malik, Natasha, Catherwood, Mark A, Hay, Jodie, Dunn, Karen M, Macdonald, Alan M, Guichard, Sylvie M, O'Rourke, Declan, Leach, Michael T, Sansom, Owen J, Cosulich, Sabina C, McCaig, Alison M, Michie, Alison M

Volltext

AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in KRAS -Mutant Tumor Models when Combined with the MEK Inhibitor, Selumetinib von Flemington, Vikki, Davies, Emma J, Robinson, David, Sandin, Linda C, Delpuech, Oona, Zhang, Pei, Hanson, Lyndsey, Farrington, Paul, Bell, Sigourney, Falenta, Katarzyna, Gibbons, Francis D, Lindsay, Nicola, Smith, Aaron, Wilson, Joanne, Roberts, Karen, Tonge, Michael, Hopcroft, Philip, Willis, Sophie E, Roudier, Martine P, Rooney, Claire, Coker, Elizabeth A, Jaaks, Patricia, Garnett, Mathew J, Fawell, Stephen E, Jones, Clifford D, Ward, Richard A, Simpson, Iain, Cosulich, Sabina C, Pease, J Elizabeth, Smith, Paul D

Volltext

Correction to: Combination of mTORC1/2 inhibitor vistusertib plus fulvestrant in vitro and in vivo targets oestrogen receptor-positive endocrine-resistant breast cancer von Pancholi, Sunil, Leal, Mariana Ferreira, Ribas, Ricardo, Simigdala, Nikiana, Schuster, Eugene, Chateau-Joubert, Sophie, Zabaglo, Lila, Hills, Margaret, Dodson, Andrew, Gao, Qiong, Johnston, Stephen R, Dowsett, Mitch, Cosulich, Sabina C, Marangoni, Elisabetta, Martin, Lesley-Ann

Volltext

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers von Hudson, Kevin, Hancox, Urs J, Trigwell, Cath, McEwen, Robert, Polanska, Urszula M, Nikolaou, Myria, Morentin Gutierrez, Pablo, Avivar-Valderas, Alvaro, Delpuech, Oona, Dudley, Phillippa, Hanson, Lyndsey, Ellston, Rebecca, Jones, Alys, Cumberbatch, Marie, Cosulich, Sabina C, Ward, Lara, Cruzalegui, Francisco, Green, Stephen

Volltext

Diverse Heterocyclic Scaffolds as Allosteric Inhibitors of AKT von Kettle, Jason G, Brown, Simon, Crafter, Claire, Davies, Barry R, Dudley, Phillippa, Fairley, Gary, Faulder, Paul, Fillery, Shaun, Greenwood, Hannah, Hawkins, Janet, James, Michael, Johnson, Keith, Lane, Clare D, Pass, Martin, Pink, Jennifer H, Plant, Helen, Cosulich, Sabina C

Volltext

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity von Langdon, Sophie, Hughes, Adina, Taylor, Molly A., Kuczynski, Elizabeth A., Mele, Deanna A., Delpuech, Oona, Jarvis, Laura, Staniszewska, Anna, Cosulich, Sabina, Carnevalli, Larissa S., Sinclair, Charles

Volltext

Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models von Wong Te Fong, Anne-Christine, Thavasu, Parames, Gagrica, Sladjana, Swales, Karen E, Leach, Martin O, Cosulich, Sabina C, Chung, Yuen-Li, Banerji, Udai

Volltext

Novel Role for p110β PI 3-Kinase in Male Fertility through Regulation of Androgen Receptor Activity in Sertoli Cells von Guillermet-Guibert, Julie, Smith, Lee B, Halet, Guillaume, Whitehead, Maria A, Pearce, Wayne, Rebourcet, Diane, León, Kelly, Crépieux, Pascale, Nock, Gemma, Strömstedt, Maria, Enerback, Malin, Chelala, Claude, Graupera, Mariona, Carroll, John, Cosulich, Sabina, Saunders, Philippa T K, Huhtaniemi, Ilpo, Vanhaesebroeck, Bart

Volltext

Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancers von Hatem, Rana, El Botty, Rania, Chateau-Joubert, Sophie, Servely, Jean-Luc, Labiod, Dalila, de Plater, Ludmilla, Assayag, Franck, Coussy, Florence, Callens, Céline, Vacher, Sophie, Reyal, Fabien, Cosulich, Sabina, Diéras, Véronique, Bièche, Ivan, Marangoni, Elisabetta

Volltext

Signaling via class IA Phosphoinositide 3-kinases (PI3K) in human, breast-derived cell lines von Juvin, Veronique, Malek, Mouhannad, Anderson, Karen E, Dion, Carine, Chessa, Tamara, Lecureuil, Charlotte, Ferguson, G John, Cosulich, Sabina, Hawkins, Phillip T, Stephens, Len R

Volltext

How is the acyl chain composition of phosphoinositides created and does it matter? von Barneda, David, Cosulich, Sabina, Stephens, Len, Hawkins, Phillip

Volltext

Genome-Wide Estrogen Receptor Activity in Breast Cancer von Farcas, Anca M, Nagarajan, Sankari, Cosulich, Sabina, Carroll, Jason S

Volltext

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor von Rodrik-Outmezguine, Vanessa S., Okaniwa, Masanori, Yao, Zhan, Novotny, Chris J., McWhirter, Claire, Banaji, Arpitha, Won, Helen, Wong, Wai, Berger, Mike, de Stanchina, Elisa, Barratt, Derek G., Cosulich, Sabina, Klinowska, Teresa, Rosen, Neal, Shokat, Kevan M.

Volltext

Bcl-2 regulates a caspase-3/caspase-2 apoptotic cascade in cytosolic extracts von SWANTON, E, SAVORY, P, CLARKE, S. C. P, WOODMAN, P

Volltext